ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2025
Can the grading of mild cardiac allograft vasculopathy be further refined? An angiographic and physiologic assessment of heart transplant recipients with ISHLT CAV 1.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antibody-independent Microvascular Inflammation Impacts Long-term Risk in Heart Transplantation.Journal of cardiac failure · 2026Article
- Vascular Remodeling in Chronic Rejection: Insights into Transplant Vasculopathy Across Solid Organ Allografts.Results and problems in cell differentiation · 2026Review
- Cardiac Allograft Vasculopathy: A Focus on Advances in Diagnosis and Management.Methodist DeBakey cardiovascular journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundCardiac allograft vasculopathy (CAV) results in impaired blood flow in both epicardial vessels and the microvasculature and is a leading cause of poor outcomes in heart transplant (HT) recipients. Most patients have mild (International Society for Heart and Lung Transplantation [ISHLT] CAV 1) disease. This study examined outcomes among those with ISHLT CAV 1 and investigated the value of physiologic assessment via cardiac positron emission tomography/computed tomography (PET/CT) for added risk stratification.
methodsCAV was graded using ISHLT criteria. Those with CAV 1 were further subgrouped into CAV 1a (maximal lesion <30% stenosis) or CAV 1b (maximal lesion ≥30% stenosis).
results299 HT recipients underwent invasive coronary angiography for CAV assessment with a median follow-up of 4.7 years. ISHLT CAV 1 was associated with a 2.9-fold risk of death/retransplantation compared to ISHLT CAV 0 (95% confidence interval [CI] 1.7-5.3, p < 0.001). Of those with ISHLT CAV 1, 12% had ISHLT CAV 1b, which was associated with a 2.8 times greater risk of death/retransplantation compared to CAV 1a (95% CI 1.4-5.9, p = 0.003). In a subgroup of 158 patients with contemporary cardiac PET/CT, among those with CAV 1a, a myocardial blood flow reserve (MBFR) ≤2 was associated with a 4.6-fold risk of death/retransplantation compared to a normal MBFR (95% CI 1.7-12.6, p = 0.001).
conclusionPatients with CAV 1b had worse outcomes than those with CAV 1a. Among those with CAV 1a, the poorer outcomes than ISHLT CAV 0 observed were predominantly associated with reduced MBFR. These data suggest additional anatomic classification and physiologic assessment can further risk stratify those with ISHLT CAV 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.